NCT04529850 2022-08-16Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck CancerGalera Therapeutics, Inc.Phase 2 Completed38 enrolled 10 charts
NCT01921426 2016-09-22A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & NeckGalera Therapeutics, Inc.Phase 1 Completed30 enrolled